Literature DB >> 28254595

Does Low-Field Intraoperative Magnetic Resonance Improve the Results of Endoscopic Pituitary Surgery? Experience of the Implementation of a New Device in a Referral Center.

Sergio García1, Luis Reyes2, Pedro Roldán2, Jorge Torales2, Irene Halperin3, Felicia Hanzu3, Cristobal Langdon4, Isam Alobid4, Joaquim Enseñat2.   

Abstract

OBJECTIVE: To assess the contribution of low-field intraoperative magnetic resonance (iMRI) to endoscopic pituitary surgery.
METHODS: We analyzed a prospective series of patients undergoing endoscopic endonasal surgery for pituitary macroadenomas assisted with a low-field iMRI (PoleStarN30, 0.15 T [Medtronic]). Clinical, radiologic, and surgical variables were analyzed and compared with our fully endoscopic historic cohort operated on without iMRI assistance. A bibliographic review of pituitary surgery assisted with iMRI was conducted.
RESULTS: Thirty patients (57% female; mean age, 55 years) were prospectively analyzed. The most frequent tumor subtype was nonfunctioning macroadenoma (50%). The average Knosp grade was 2.3 and mean tumor size was 18 mm. Surgical and positioning time were 102 and 47 minutes, respectively. Hospital stay and complication rates were similar to our historical cohort for pituitary surgery. Mean follow-up was 10 months. Complete resection (CR) was achieved in 83% of patients. Seven patients (23%) benefited from iMRI assistance and achieved a CR in their surgeries. All patients except 1 experienced hormonal activity remission. iMRI sensitivity and specificity was 0.8 and 1, respectively. Although not statistically significant, CR rates were globally 11.5% superior in iMRI series compared with our historical cohort. This difference was independent of cavernous sinus invasiveness grade (CR rate increased 12.5% for Knosp grade 0-2 and 8.1% for Knosp grade 3-4).
CONCLUSIONS: Low-field iMRI is a useful and safe assistance even in advanced surgical techniques such as endoscopy. Its contribution is limited by the intrinsic features of the tumor. Further randomized studies are required to confirm the cost-effectiveness of iMRI in pituitary surgery.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Endoscopic; Extent of resection; Intraoperative magnetic resonance; Low field; Macroadenoma; Pituitary

Mesh:

Substances:

Year:  2017        PMID: 28254595     DOI: 10.1016/j.wneu.2017.02.094

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  5 in total

1.  Cost-Effectiveness of Low-Field Intraoperative Magnetic Resonance in Glioma Surgery.

Authors:  Sergio Garcia-Garcia; Borja García-Lorenzo; Pedro Roldan Ramos; Jose Juan Gonzalez-Sanchez; Diego Culebras; Gabriela Restovic; Estanis Alcover; Imma Pons; Jorge Torales; Luis Reyes; Laura Sampietro-Colom; Joaquim Enseñat
Journal:  Front Oncol       Date:  2020-11-02       Impact factor: 6.244

Review 2.  Impact of intraoperative magnetic resonance imaging on gross total resection, extent of resection, and residual tumor volume in pituitary surgery: systematic review and meta-analysis.

Authors:  Victor E Staartjes; Alex Togni-Pogliorini; Vittorio Stumpo; Carlo Serra; Luca Regli
Journal:  Pituitary       Date:  2021-05-04       Impact factor: 4.107

Review 3.  Perioperative management of endoscopic transsphenoidal pituitary surgery.

Authors:  Martin Hanson; Hao Li; Eliza Geer; Sasan Karimi; Viviane Tabar; Marc A Cohen
Journal:  World J Otorhinolaryngol Head Neck Surg       Date:  2020-03-20

Review 4.  Low-field MRI: An MR physics perspective.

Authors:  José P Marques; Frank F J Simonis; Andrew G Webb
Journal:  J Magn Reson Imaging       Date:  2019-01-13       Impact factor: 4.813

5.  Impact of Intraoperative 3-Tesla MRI on Endonasal Endoscopic Pituitary Adenoma Resection and a Proposed New Scoring System for Predicting the Utility of Intraoperative MRI.

Authors:  Masahiro Tanji; Hiroharu Kataoka; Masahiro Kikuchi; Tatsunori Sakamoto; Fumihiko Kuwata; Mami Matsunaga; Takayuki Nakagawa; Yohei Mineharu; Yoshiki Arakawa; Kazumichi Yoshida; Susumu Miyamoto
Journal:  Neurol Med Chir (Tokyo)       Date:  2020-10-21       Impact factor: 1.742

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.